Dexrazoxane reduces tissue damage caused by doxorubicin (and similar cancer chemotherapy medications). This tissue damage is partly caused by iron in the body binding to doxorubicin, which leads to toxic side effects. Dexrazoxane is thought to bind to iron instead, which may protect the heart and the tissue around the injection site from doxorubicin's toxic effects.
Dexrazoxane reduces the risk of heart damage caused by doxorubicin treatment. This side effect limits the length of time you can be treated with doxorubicin. Dexrazoxane use allows you to continue doxorubicin treatment for longer. When used for this purpose, dexrazoxane treatment is usually started after you have received several doses of doxorubicin. It is usually not given with the first doses of doxorubicin since doing so may reduce the effectiveness of doxorubicin.
Dexrazoxane is also used to reduce serious tissue injury and the need for surgery if doxorubicin or a related chemotherapy drug has leaked out of the vein into the surrounding tissue.
How To Use
Read the Patient Information Leaflet if available from your pharmacist before you start using dexrazoxane. If you have any questions, ask your doctor or pharmacist.
This medication is usually given by injection into a vein by a health care professional.
When used to reduce the risk of heart damage, each dose of dexrazoxane is usually started no more than 30 minutes before each doxorubicin dose.
When used to reduce the risk of tissue injury from chemotherapy injection leakage, dexrazoxane is usually given as soon as possible (within 6 hours of the injection leakage) once daily for 3 days, or as directed by your doctor.
If skin contact occurs, wash with plenty of soap and water. If irritation occurs, contact your doctor right away.
Heart damage may occur at any time with doxorubicin treatment, even years after the end of your doxorubicin treatment. Tell your doctor right away if you have symptoms of heart damage such as sudden nighttime shortness of breath, difficulty breathing while lying down, or shortness of breath when active.